PROPANC BIOPHARMA, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
PROPANC BIOPHARMA, INC. (PPCB) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $443.70 thousand as of 2026-03-31, per its S-1 filed 2026-07-17.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-07-17
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $443.70K.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $561.24K.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $602.74K.
- 2025-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $12.09K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-03-31 | $443.70K S-1 · filed 2026-07-17 |
| 2025-12-31 | $561.24K S-1 · filed 2026-04-10 |
| 2025-09-30 | $602.74K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $12.09K S-1 · filed 2026-07-17 |
| 2025-03-31 | $50.76K S-1 · filed 2026-07-17 |
| 2024-12-31 | $14.63K S-1 · filed 2026-04-10 |
| 2024-09-30 | $9.27K 10-Q · filed 2025-11-14 |
| 2024-06-30 | $21.09K S-1 · filed 2026-07-17 |
| 2024-03-31 | $6.22K 10-Q · filed 2025-05-15 |
| 2023-12-31 | $71.65K 10-Q · filed 2025-02-14 |
| 2023-09-30 | $6.63K 10-Q · filed 2024-11-14 |
| 2023-06-30 | $10.05K S-1 · filed 2026-07-17 |
| 2023-03-31 | $93.24K 10-Q · filed 2024-05-15 |
| 2022-12-31 | $24.48K 10-Q · filed 2024-02-20 |
| 2022-09-30 | $19.40K 10-Q · filed 2023-11-14 |
| 2022-06-30 | $4.07K 10-K · filed 2024-09-30 |
| 2022-03-31 | $133.88K 10-Q · filed 2023-05-15 |
| 2021-12-31 | $73.62K 10-Q · filed 2023-02-10 |
| 2021-09-30 | $45.82K 10-Q · filed 2022-11-14 |
| 2021-06-30 | $2.25K 10-K · filed 2023-09-28 |
| 2021-03-31 | $14.44K 10-Q · filed 2022-05-16 |
| 2020-12-31 | $21.24K 10-Q · filed 2022-02-14 |
| 2020-09-30 | $51.22K 10-Q · filed 2021-11-12 |
| 2020-06-30 | $67.01K 10-K · filed 2022-09-28 |
| 2020-03-31 | $26.96K 10-Q · filed 2021-05-14 |
| 2019-12-31 | $12.02K 10-Q · filed 2021-02-12 |
| 2019-09-30 | $96.12K 10-Q · filed 2020-11-16 |
| 2019-06-30 | $2.39K 10-K · filed 2021-09-28 |
| 2019-03-31 | $107.21K 10-Q · filed 2020-05-15 |
| 2018-12-31 | $124.54K 10-Q · filed 2020-02-14 |
| 2018-09-30 | $38.91K 10-Q · filed 2019-11-14 |
| 2018-06-30 | $19.92K 10-K · filed 2020-10-01 |
| 2018-03-31 | $9.30K 10-Q · filed 2019-05-15 |
| 2017-12-31 | $112.50K 10-Q · filed 2019-02-14 |
| 2017-06-30 | $69.04K 10-K · filed 2019-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |